Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

83.81USD
15 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$83.81
Open
--
Day's High
--
Day's Low
--
Volume
147
Avg. Vol
5,294,761
52-wk High
$85.99
52-wk Low
$61.55

Select another date:
Photo

Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO, July 16 Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

Abbott Labs quarterly beat overshadowed by unchanged forecast

Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast

April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

Abbott Lab's first-quarter sales beat expectations

April 17 Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.

U.S. joins case against Abbott's Alere over diabetic tests

The U.S. Justice Department on Tuesday said it has joined a whistleblower lawsuit alleging Abbott Laboratories' Alere Inc unit defrauded Medicare into paying for unnecessary testing supplies for diabetic patients.

Abbott's Alere to resolve securities fraud case for $20 million

Alere Inc, now a unit of Abbott Laboratories Inc, has agreed to pay $20 million to resolve claims it made false and misleading statements to investors in the lead up to the announcement of a deal to sell the diagnostic testing company to Abbott.

Abbott escapes lawsuit over recalled St. Jude defibrillators

Jan 25 - Abbott Laboratories has escaped a proposed class action lawsuit alleging its subsidiary St. Jude Medical concealed a potentially deadly battery defect in some of its cardiac defibrillators for years before finally recalling them in 2016.

Select another date: